Dr. Gu is a dedicated dermatologist specializing in a variety of skin conditions. He graduated Summa Cum Laude from Columbia University’s School of Engineering and Applied Science with a Bachelor of Science in engineering. Dr. Gu went on to obtain his medical degree at Columbia University’s College of Physicians and Surgeons, during which time he completed a research fellowship in cutaneous oncology at the Institute for Cancer Genetics and presented his groundbreaking findings at the Society for Investigative Dermatology.

After medical school, Dr. Gu completed his internship in internal medicine at the University of Pittsburgh Medical Center and returned to New York Presbyterian Hospital-Columbia University for his specialty training in dermatology. He has remained active in the dermatology community and has presented at various national and regional conferences including the Dermatologic Society of Greater New York.

Throughout his career, Dr. Gu has demonstrated a commitment to advancing dermatology through rigorous research, clinical excellence, and compassionate patient care. He continues to pursue his passion for understanding complex dermatologic conditions and translating research findings into practical advancements that benefit patients worldwide.

Publications & Presentations

• Society Presentations: Targeting the JAK/STAT pathway for CTCL therapy (Society for Investigative Dermatology, Annual 2019  Meeting; New York Dermatological Society, February 2022).  
• Grand Rounds: Paraneoplastic neurological syndrome in Merkel Cell Carcinoma (Columbia University, 2019), Sjogren-Larsson  Syndrome (Columbia University, 2023), CAR-T Therapy Related Cutaneous Adverse Events (Columbia University, 2022)  
• Cortes J, Patrone C, Quinn C, Gu Y, Sanchez-Martin M, Mackey A, Cooke A, Shish B, Laurent A, Trager M, Ferrando A, Geskin L,  Palomero T (2021). Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.  Journal of Investigative Dermatology, 141(12):2908-2920.e7. doi: 10.1016/j.jid.2021.04.023  
• Gu YD, Perez-Duran P, Oshima K, Rodriguez-Cortes C, Ferrando A, Palomero T, Geskin L (2019). Targeting the JAK/STAT  pathway for CTCL therapy. Journal of Investigative Dermatology, Society of Investigative Dermatology 2019 Annual Meeting 
• Queen D, Gu Y, Lopez A, Chen D, Geskin L (2019). Paraneoplastic Cerebellar Ataxia in Merkel Cell Carcinoma of Unknown  Primary. JAAD Case Reports, 5(5):398-400. doi: 10.1016/j.jdcr.2019.02.004 
• Gu YD, Chen C, Geskin L (2019). A Review of Primary Cutaneous CD30+ Lymphoproliferative Disorders. Hematology/Oncology  Clinics of North America, 33 (1). doi.org/10.1016/j.hoc.2018.08.003  
• Gee M, Gu Y, Fields JR, Shiao YH (2012). Stabilization of ribozyme-like cis-noncoding rRNAs induces apoptotic and nonapoptotic  death in lung cells. Cell Death and Disease, 3, e281. doi: 10.1038/cddis.2012.19 
 
• Shiao YH, Lupascu ST, Gu YD, Kasprzak W, Hwang CJ, Fields JR, Leighty RM, Quiñones O, Shapiro BA, Alvord WG, Anderson  LM (2009). An intergenic non-coding rRNA correlated with expression of the rRNA and frequency of an rRNA single nucleotide  polymorphism in lung cancer cells. PLoS One, 4(10), e7505. doi: 10.1371/journal.pone.0007505